Stay updated on LDX Safety in Children & Adolescents Clinical Trial
Sign up to get notified when there's something new on the LDX Safety in Children & Adolescents Clinical Trial page.

Latest updates to the LDX Safety in Children & Adolescents Clinical Trial page
- Check7 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed study information regarding the efficacy of Lisdexamfetamine Dimesylate (LDX) for ADHD in children and adolescents, and the revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference21%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.9%
- Check87 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.9%
Stay in the know with updates to LDX Safety in Children & Adolescents Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LDX Safety in Children & Adolescents Clinical Trial page.